Alnylam Pharmaceuticals, Inc.
ALNY
$332.92
$1.680.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 186.42M | 251.08M | -66.28M | -57.48M | -83.76M |
| Total Depreciation and Amortization | 13.51M | 13.80M | 13.94M | 14.41M | 14.17M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.78M | 264.88M | 155.99M | 141.81M | 83.23M |
| Change in Net Operating Assets | -73.15M | -204.66M | 50.08M | -217.05M | -108.30M |
| Cash from Operations | 163.56M | 325.11M | 153.73M | -118.31M | -94.66M |
| Capital Expenditure | -23.29M | -12.14M | -14.29M | -8.97M | -9.09M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.87M | 513.25M | -127.09M | 122.74M | -43.82M |
| Cash from Investing | -37.17M | 501.11M | -141.38M | 113.77M | -52.91M |
| Total Debt Issued | -680.00K | 646.37M | -- | -- | -- |
| Total Debt Repaid | -52.25M | -1.14B | -- | -- | -- |
| Issuance of Common Stock | 41.70M | 77.74M | 81.22M | 49.37M | 36.28M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 56.55M | -32.08M | -27.47M | -5.28M | -5.28M |
| Cash from Financing | 45.32M | -448.35M | 53.76M | 44.08M | 31.00M |
| Foreign Exchange rate Adjustments | -5.70M | -927.00K | 27.51M | 14.06M | -17.27M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 166.01M | 376.94M | 93.61M | 53.60M | -133.85M |